TickerFacts.

Company research / MGNX

Macrogenics Inc (MGNX)

Build a valuation ↗↓ Download CSV

SEC name MACROGENICS INC · CIK 0001125345 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Macrogenics Inc reported revenue of $149.50M. Revenue fell 0.3% from the prior annual period.

Key ratios (year ended 2025-12-31)

-48.7%
Operating margin
-49.9%
Net margin
-134.2%
Return on year-end equity
-0.3%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-10-07

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30		2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenuen/a$149.50M$149.96M$58.75M$151.94M$77.45M$104.88M$64.19M$60.12M$157.74M$91.88M
Cost of Revenuen/a$0$847.0K$619.0K$3.35M$2.65M$0$0n/an/an/a
R&D Expense$140.44M$147.17M$177.19M$166.58M$207.03M$214.58M$193.20M$195.31M$190.83M$147.23M$122.09M
Operating Incomen/a-$72.84M-$110.58M-$168.24M-$121.42M-$202.79M-$131.06M-$177.19M-$171.21M-$22.14M-$60.04M
Depreciation & Amortization$5.89M$7.17M$7.54M$9.64M$11.87M$11.26M$11.96M$12.31M$9.16M$7.23M$7.61M
EBITDAn/a-$65.67M-$103.04M-$158.60M-$109.55M-$191.54M-$119.10M-$164.88M-$162.05M-$14.91M-$52.43M
Net Income-$14.59M-$74.62M-$66.97M-$9.06M-$119.76M-$202.12M-$129.74M-$151.81M-$171.45M-$19.63M-$58.53M
EPS (Diluted)n/a-$1.18-$1.07-$0.15-$1.95-$3.37-$2.47n/an/an/an/a
Total Assets$345.41M$256.85M$261.65M$298.42M$280.47M$335.25M$378.74M$312.50M$332.13M$373.88M$311.26M
Total Liabilities$302.54M$201.25M$145.60M$145.81M$138.46M$95.63M$82.86M$81.87M$89.25M$74.64M$42.51M
Shareholders' Equity$42.87M$55.59M$116.06M$152.61M$142.01M$239.62M$295.88M$230.63M$242.88M$299.24M$268.75M
Cash & Equivalents$113.91M$57.22M$182.84M$100.96M$108.88M$123.47M$181.13M$126.47M$220.13M$211.73M$84.10M
Operating Cash Flow-$63.72M-$81.04M-$68.37M-$78.20M-$86.96M-$143.83M-$111.90M-$134.27M-$153.23M$14.40Mn/a
Capital Expenditures$1.82M$1.91M$3.71M$1.76M$3.62M$6.20M$5.91M$4.29M$24.95M$29.40M$11.38M
Free Cash Flow-$65.54M-$82.95M-$72.08M-$79.97M-$90.58M-$150.03M-$117.80M-$138.56M-$178.19M-$15.00Mn/a
Shares Outstanding63.65M63.32M62.82M62.07M61.70M61.31M56.24M48.96M42.35M36.86M34.87M
Weighted Average Diluted Sharesn/a63.16M62.62M61.93M61.43M59.94M52.44M48.08Mn/a36.10M34.69M
EPS (Basic)n/a-$1.18-$1.07-$0.15-$1.95-$3.37-$2.47n/an/an/an/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView